2395
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Shin Nippon Biomedical Laboratories, Ltd. operates in three main segments: Contract Research Organization (CRO) services, Translational Research (TR), and the Medipolis business. In the CRO segment, the company provides non-clinical and clinical trial support to pharmaceutical companies, utilizing facilities such as the Safety Research Institute and the Drug Metabolism Analysis Center. Key subsidiaries include Shin Nippon Kagaku Inarisearch Center, CLINICAL STUDY SUPPORT, and the joint venture Shin Nippon Kagaku PPD, which manages clinical trials. The TR segment focuses on the company's proprietary SMART (Simple MucoAdhesive Release Technology) platform for nasal drug delivery, supporting spin-out companies like Satsuma Pharmaceuticals, Inc. and SNLD in developing treatments for conditions such as migraine and Parkinson's disease. The Medipolis segment involves geothermal power generation and hospitality operations, including the hotel Bettei Amaguruka and HOTEL Freesia. The company also engages in a US real estate business through SNBL U.S.A., Ltd. and maintains a presence in Asia via Shin Nippon Kagaku (Asia) Co., Ltd. and SHIN NIPPON BIOMEDICAL LABORATORIES (CAMBODIA) LIMITED, which handles non-human primate breeding and quarantine.

Summarised from the annual report, fiscal year ended Mar 2026

Industry Diagnostics & Research Homepage snbl.co.jp
Sector Healthcare IR page snbl.com
Tags
contract research organization, non-clinical trials, clinical trials, nasal drug delivery, translational research, geothermal power, hospitality, non-human primates, pharmaceutical development, Shin Nippon Kagaku Inarisearch Center, CLINICAL STUDY SUPPORT, SNBL U.S.A. Ltd., University Medicines International LLC., Shin Nippon Kagaku (Asia) Co. Ltd., SHIN NIPPON BIOMEDICAL LABORATORIES (CAMBODIA) LIMITED, ANGKOR PRIMATES CENTER INC., Shin Nippon Kagaku PPD, ANKAI YIBO (Zhaoqing) Biotechnology Co. Ltd., Satsuma Pharmaceuticals Inc., SNLD, Gemseki Investment, NDP Pharmaceuticals Inc., SGG Management Services LLC., Ruika Therapeutics Inc., SBI US Gateway Fund LP, AMAFURU & Co. Ltd., Medipolis Energy, Green Hydrogen, Bettei Amaguruka, HOTEL Freesia, Medipolis SNBL Asset Management, Fureai Sasaai, Trunk Solution, Shin Nippon Sogo Construction, FREESIA HD INC., Shin Nippon Kagaku Tasso, JRMPC, NANA, Wave Life Sciences Ltd.
Press page —

Metrics

Valuation  
Market cap ¥ 54.039B
Market cap (USD) $ 337.747M
P/E 9.47
PEG —
P/BV 1.36
P/S 1.53
P/OCF 4.46
P/FCF 10.24
Dividend yield 3.9%
Turnover / mcap —
Returns  
ROE 10.9%
ROI 5.4%
ROIC 2.3%
Profit margin 14.0%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -9.0%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 15
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 32.525B 32.414B 26.45B 25.091B 17.748B 15.111B 14.561B 15.659B 16.601B 17.244B 14.75B 17.835B 16.926B 17.154B
Net profit 4.567B 4.925B 5.531B 6.06B 7.128B 3.662B 2.55B 1.95B -3.556B -915.938M 2.646B -1.386B -754.991M -1.153B
Free cash flow 2.991B -3.897B -6.499B -951.696M 4.339B 3.629B 1.788B 1.793B 326.003M -1.866B -5.148B — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 1.414K 1.429K 1.516K 2.751K 1.698K 697.62 526.75 900.43 589.1 420.54 420.54 — — —
Price performance 12m -0.01 -0.06 -0.45 0.62 1.43 0.32 -0.42 0.53 0.4 0 — — — —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (JPY) 2.84B 2.56B 1.99B 2.6B 2.95B 3.5B 7.74B 9.77B 10.5B 10.5B
↳ YoY growth -8.5% -10.1% -22.3% +31.1% +13.4% +18.5% +121.1% +26.1% +7.4% +0.3%
↳ 5y CAGR -1.0% +4.3% +24.8% +37.5% +32.1% +28.9%
Borrowings, current (JPY) 11.6B 11.5B 11.3B 6B 3.49B 2.94B 8.92B 7.83B 11.8B 19.7B
Borrowings, non-current (JPY) 10.8B 6.92B 3.89B 8.22B 8.67B 5.81B 9.48B 18.1B 22.3B 21.1B
Bonds payable (JPY) 50M — — — — — — — — —
Lease liabilities (JPY) 492M 485M 708M 707M 529M 386M 357M 213M 425M 468M
Cash and deposits (JPY) 7.42B 5.31B 5.14B 5.25B 7.23B 6.63B 10.5B 10.3B 12B 18.5B
Intangible assets (JPY) 371M 289M 92.5M 194M 214M 212M 1.7B 2.16B 2.1B 2.12B
Net debt (borrowings + leases - cash) (JPY) 15.5B 13.6B 10.8B 9.67B 5.46B 2.51B 8.23B 15.9B 22.4B 22.7B
Cash flow detail
Operating cash flow (JPY) -850M 1.34B 2.89B 3.02B 4.75B 5.95B 4B 2.11B 7.04B 8.33B
Purchases of property, plant and equipment (JPY) -790M -1.01B -1.07B -1.15B -1.07B -1.54B -4.84B -8.58B -10.9B -5.17B
Purchases of intangible assets (JPY) -226M -5.37M -31.9M -82.7M -50.9M -71.2M -116M -22.2M -79.2M -162M
Change in receivables (cash effect) (JPY) 193M 286M -149M -619M -343M -481M -938M -957M -871M -597M
Change in inventories (cash effect) (JPY) -70.7M 398M -424M -445M -71.7M -371M -968M -5B -149M -2.41B
Change in payables (cash effect) (JPY) -65.6M -2.32M 119M 82.7M -24.2M -36.7M -268M -177M -9.82M -59M
Dividends paid (cash effect) (JPY) — — — -124M -206M -827M -2.48B -2.07B -2.1B -2.08B
Share buybacks (cash effect) (JPY) — — — — — — — — -325,000 -34,000
Interest paid (cash effect) (JPY) -409M -347M -338M -288M -172M -118M -118M -126M -217M -207M
Income taxes paid (cash effect) (JPY) -1.38B -149M -152M -82.9M -480M -1.01B -1.44B -1.22B -2.01B -2.18B
Operating cash flow before change in receivables (JPY) -1.04B 1.06B 3.04B 3.64B 5.09B 6.43B 4.94B 3.06B 7.91B 8.92B
Free cash flow (OCF - PPE - intangibles) (JPY) -1.87B 326M 1.79B 1.79B 3.63B 4.34B -952M -6.5B -3.9B 2.99B
Income detail
Research and development expense (JPY) 601M 518M 340M 401M 392M 425M 683M 1.74B 2.22B 2.4B
↳ 5y CAGR -13.6% -6.7% +5.7% +38.7% +40.8% +43.7%
Total comprehensive income (JPY) 4.81B 4B 2.23B -11.9B -328M 4.65B 9.13B 9.92B 7.9B 5.13B
Comprehensive income to owners (JPY) 4.79B 3.97B 2.22B -12B -345M 4.61B 9.14B 9.93B 7.96B 5.14B
Provision for credit losses (JPY) 7.03M 13.7M 74.2M 131,000 — 169,000 64.8M 2.18M 308M 42.8M
Credit cost ratio (credit losses / average receivables) (%) 0.2% 0.5% 3.3% 0.0% — 0.0% 1.2% 0.0% 3.0% 0.4%
Segments
US Asset Management · Segment revenue (JPY) — — — — — — — — 46M 184M
↳ YoY growth +301.0%
US Asset Management · Segment operating income (JPY) — — — — — — — -20.2M -60.5M -1.49M
Reported Jun 30, 2017 Jun 28, 2018 Jul 1, 2019 Jun 26, 2020 Jun 30, 2021 Jun 29, 2022 Jun 28, 2023 Jun 27, 2025 Jun 27, 2025 Jun 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Shin Nippon Biomedical Laboratories, Ltd. (ticker 2395), listed in Japan.

Company History

Date Change Detail
Jul 14, 2022 Acquired Acquired Ina Research Inc. (EDINET code E20922). Its filings from before the deal are on its own company page, not shown here.

ETFs Holding Shin Nippon Biomedical Laboratories, Ltd.

ETF Weight in ETF Shares Market value As of
DISV 0.01% 48,600 $ 373.542K Nov 12, 2026
DFIS 0.00% 36,400 $ 279.772K Nov 12, 2026
DXIV 0.00% 1,400 $ 10.76K Nov 12, 2026
DFIC 0.00% 33,300 $ 255.946K Nov 12, 2026
DFAX 0.00% 12,900 $ 99.15K Nov 12, 2026
DFAI 0.00% 9,400 $ 72.249K Nov 12, 2026
AVDV 0.00% 1,000 $ 7,558.98 Nov 16, 2026
AVDS 0.00% 2,100 $ 15.874K Nov 16, 2026